Company Profile

Company Profile

Introduction

Having pioneered the field, Organogenesis Inc. is a commercial leader in regenerative medicine, focused in the areas of bio-active wound healing and soft tissue regeneration.

Founded

The company was originally founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT).

Mission

The mission of Organogenesis is to bring the medical marvel of regenerative medicine to patients and standardize its use in everyday medical care.

Initially our corporate mission was to "introduce regenerative medicine to the world." With more than 1 million units of Apligraf® and Dermagraft® - the leading regenerative medicine products in the world - shipped for patient use, we believe that we have successfully achieved this goal.

Across the organization, our mission guides our actions. We work to build brands and services that integrate the benefits of regenerative medicine into every day medical practice.

Areas of Focus

  • Bio-active wound healing
  • Soft tissue regeneration

Headquarters

We are headquartered in Canton, Massachusetts which is also the site of our Apligraf manufacturing and distribution facilities.

Our Dermagraft manufacturing and distribution facilities are based in San Diego, California.

Our European headquarters offices are located in Switzerland.

Employees

Over 600 employees in the U.S.

Our executive team comprises talented individuals with over 100 years of collective regenerative medicine experience.

Major Milestones

1998: First FDA approval of a living, allogeneic, cell based product (Apligraf® approved for the treatment of venous leg ulcers).

2000: Apligraf® FDA approved for the treatment of diabetic foot ulcers.

2004: Launch of full USA sales and marketing organization.

2006: European office established.

2009: Commenced expansion of Organogenesis' Massachusetts headquarters campus.

2011: Exceeded $100 million in revenue and 500 employees.

2012: First FDA approval of a living, allogeneic, cell based product (GINTUIT™) for the treatment of oral regeneration.

2014: Acquired Dermagraft (approved for treating chronic diabetic foot ulcers).